DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

Inclusion Criteria:

• Is HIV-1 positive with plasma HIV-1 RNA ≥500 copies/mL at screening

• Is naïve to antiretroviral therapy (ART) defined as having received no prior therapywith any antiretroviral agent following a diagnosis of HIV-1 infection

• If female, is not a participant of childbearing potential (POCBP); or if a POCBP, isnot pregnant or breastfeeding, and is willing to use an acceptable contraceptivemethod or abstain from heterosexual intercourse for study duration

Exclusion Criteria:

• Has HIV-2 infection

• Has hypersensitivity or other contraindication to any of the components of the studyinterventions as determined by the investigator

• Has a diagnosis of an active AIDS-defining opportunistic infection within 30 daysprior to screening

• Has active hepatitis B infection (defined as hepatitis B surface antigen [HBsAg]-positive or HBV deoxyribonucleic acid [DNA]-positive).

• Has chronic hepatitis C virus (HCV) infection (detectable HCV ribonucleic acid [RNA]) and lab values are consistent with cirrhosis

• Has a history of malignancy ≤5 years prior to providing documented informed consentexcept for adequately treated basal cell or squamous cell skin cancer, in situcervical cancer, or cutaneous Kaposi's sarcoma

• Has a history or current evidence of any condition (including active tuberculosisinfection), therapy, laboratory abnormality, or other circumstance (including drugor alcohol use or dependence) that might, in the opinion of the investigator,confound the results of the study or interfere with the participant's participationfor the full duration of the study, such that it is not in the best interest of theparticipant to participate